Advertisement

Opiate Pharmacokinetics: In Vivo Receptor Binding and Pharmacological Effects

  • W. Sadée
  • J. S. Rosenbaum

Abstract

The discovery of a specific cerebral opiate receptor in 1973 (reviewed in reference 1) rapidly led to the detection of endogenous peptides as putative neurotransmitters/modulators associated with the opiate receptor (2). However, Martin et al. (3) presented the first pharmacological evidence that the opiate receptor system consists of several subpopulations of distinct receptor sites, and it was subsequently postulated that there are multiple opiate receptors and endogenous ligands (2), including Leu-enkephalin, Met-enkephalin, β-endorphin and dynorphin. In [3H]-ligand binding studies on rodent brain homogenates (4), at least three distinct binding sites were detectable; the μ, δ and κ/σ sites. Despite the rapid advance in opiate molecular pharmacology, several key questions concerning the molecular mechanisms remain unsolved. We are studying the problem with regard to which receptor subsites mediate the different pharmacological effects of the opiates. Effects include analgesia, dependence, tolerance and many other behavioral and peripheral changes that are seemingly unrelated to each other.

Keywords

Receptor Occupancy Opiate Receptor Opiate Antagonist Ligand Binding Study Saturation Isotherm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S.H. Snyder and R. Simantov, The opiate receptor and opioid peptides, J. Neurochem. 28: 13 – 20 (1977).PubMedCrossRefGoogle Scholar
  2. 2.
    J.A.H. Lord, A.A. Waterfield, J. Hughes and H.W. Kosterlitz, Endogenous opioid peptides: Multiple agonists and receptors, Nature 267: 495 – 499 (1977).PubMedCrossRefGoogle Scholar
  3. 3.
    W.R. Martin, C.G. Eades, J.A. Thompson, R.E. Huppler and P.E. Gilbert, The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharmacol. Exp. Ther. 197: 517 – 532 (1976).PubMedGoogle Scholar
  4. 4.
    K.-J. Chan, E. Hazum and P. Cuatrecasas, Novel opiate binding sites selective for benzomorphan drugs, Proc. Natl. Acad. Sci. USA. 78: 4141 – 4145 (1981).CrossRefGoogle Scholar
  5. 5.
    D.C. Perry, J.S. Rosenbaum, M. Kurowski and W. Sadée, [3H]- Etorphine receptor bindingin vivo: Small fractional occupancy elicits analgesia, Mol. Pharmacol. 21: 272 – 279 (1982).PubMedGoogle Scholar
  6. 6.
    D.C. Perry, K.B. Mullis, S. 0ie and W. Sadée, Opiate antagonist receptor binding in vivo: Evidence for a new receptor binding model, Brain Res. 199: 49 – 61 (1980).PubMedCrossRefGoogle Scholar
  7. 7.
    M. Kurowski, J.S. Rosenbaum, D.C. Perry and W. Sadée, [3H]- Etorphine and [3H]-diprenorphine receptor bindingin vitroandin vivo: Differential effects of Na+ and GPP(NH)P, Brain Res. 249: 345 – 352 (1982).PubMedCrossRefGoogle Scholar
  8. 8.
    W. Sadée, A. Pfeiffer and A. Herz, Opiate receptor: Multiple effects of metal ions, J. Neurochem. 36: 659 – 667 (1982).CrossRefGoogle Scholar
  9. 9.
    J. Grevel and W. Sadge, An opiate binding site in the rat brain is highly selective for 4,5-epoxymorphinans, Science 221: 1198 – 1201 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • W. Sadée
    • 1
  • J. S. Rosenbaum
    • 1
  1. 1.School of PharmacyUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations